28.52
-0.19 (-0.66%)
| Penutupan Terdahulu | 28.71 |
| Buka | 28.13 |
| Jumlah Dagangan | 1,920,400 |
| Purata Dagangan (3B) | 1,675,950 |
| Modal Pasaran | 4,533,681,664 |
| Harga / Pendapatan (P/E Ke hadapan) | 90.91 |
| Harga / Jualan (P/S) | 5.78 |
| Harga / Buku (P/B) | 7.37 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2025 - 9 May 2025 |
| Margin Keuntungan | -64.37% |
| Margin Operasi (TTM) | -48.91% |
| EPS Cair (TTM) | -3.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -30.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 332.93% |
| Nisbah Semasa (MRQ) | 8.47 |
| Aliran Tunai Operasi (OCF TTM) | -500.95 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -352.83 M |
| Pulangan Atas Aset (ROA TTM) | -9.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -93.10% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Ionis Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.83% |
| % Dimiliki oleh Institusi | 105.07% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Tweedy, Browne Co Llc | 31 Dec 2024 | 3,248,863 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 70.00 (RBC Capital, 145.44%) | Beli |
| Median | 45.00 (57.78%) | |
| Rendah | 39.00 (Redburn Atlantic, 36.75%) | Pegang |
| Purata | 52.57 (84.33%) | |
| Jumlah | 4 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 31.25 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 08 Apr 2025 | 60.00 (110.38%) | Beli | 28.52 |
| 20 Feb 2025 | 60.00 (110.38%) | Beli | 32.69 | |
| HC Wainwright & Co. | 07 Apr 2025 | 45.00 (57.78%) | Beli | 28.52 |
| Redburn Atlantic | 31 Mar 2025 | 39.00 (36.75%) | Pegang | 30.17 |
| JP Morgan | 24 Mar 2025 | 45.00 (57.78%) | Pegang | 33.45 |
| 11 Mar 2025 | 47.00 (64.80%) | Pegang | 33.03 | |
| BMO Capital | 20 Feb 2025 | 45.00 (57.78%) | Pegang | 32.69 |
| Citigroup | 20 Feb 2025 | 64.00 (124.40%) | Beli | 32.69 |
| RBC Capital | 20 Feb 2025 | 70.00 (145.44%) | Beli | 32.69 |
| 15 Jan 2025 | 70.00 (145.44%) | Beli | 33.21 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |